Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
© The Author(s), 2023..
Background: The use of PARP inhibitor (PARPi) has shown a considerable benefit in progression-free survival (PFS) in relapsed, platinum-sensitive epithelial ovarian cancer (OC).
Objective: Our study aimed to investigate the impact of the last platinum-based chemotherapy treatment in response to PARPi.
Design: Retrospective cohort study.
Patients and methods: The study involved 96 consecutive, pretreated, platinum-sensitive advanced OC patients. Demographics and clinical data were retrieved from clinical records. PFS and overall survival (OS) were calculated from the start of PARPi.
Results: Germline BRCA mutation was investigated in all cases. Platinum-based chemotherapy before PARPi maintenance therapy included pegylated liposomal doxorubicin-oxaliplatin (PLD-Ox) in 46 patients (48%) and other platinum-based chemotherapy in 50 patients (52%). During a median follow-up of 22 months from the beginning of PARPi therapy, 57 patients relapsed (median PFS: 12 months) and 64 patients died (median OS: 23 months). During multivariable analysis, receiving PLD-Ox before PARPi was associated with improved PFS [hazard ratio (HR): 0.46, 95% CI: 0.26-0.82] and OS (HR: 0.48, 95% CI: 0.27-0.83). In 36 BRCA-mutated patients, PLD-Ox was associated with improved PFS (2-year PFS: 70.0% versus 25.0%, p = 0.02).
Conclusion: Receiving PLD-Ox before PARPi may improve prognosis in platinum-sensitive advanced OC patients and may provide advantages in the BRCA-mutated subgroup.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Therapeutic advances in medical oncology - 15(2023) vom: 31., Seite 17588359231173181 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nicoletto, Maria Ornella [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRCA mutated |
|---|
| Anmerkungen: |
Date Revised 01.07.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/17588359231173181 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358621240 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358621240 | ||
| 003 | DE-627 | ||
| 005 | 20231226075134.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/17588359231173181 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM358621240 | ||
| 035 | |a (NLM)37360767 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nicoletto, Maria Ornella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), 2023. | ||
| 520 | |a Background: The use of PARP inhibitor (PARPi) has shown a considerable benefit in progression-free survival (PFS) in relapsed, platinum-sensitive epithelial ovarian cancer (OC) | ||
| 520 | |a Objective: Our study aimed to investigate the impact of the last platinum-based chemotherapy treatment in response to PARPi | ||
| 520 | |a Design: Retrospective cohort study | ||
| 520 | |a Patients and methods: The study involved 96 consecutive, pretreated, platinum-sensitive advanced OC patients. Demographics and clinical data were retrieved from clinical records. PFS and overall survival (OS) were calculated from the start of PARPi | ||
| 520 | |a Results: Germline BRCA mutation was investigated in all cases. Platinum-based chemotherapy before PARPi maintenance therapy included pegylated liposomal doxorubicin-oxaliplatin (PLD-Ox) in 46 patients (48%) and other platinum-based chemotherapy in 50 patients (52%). During a median follow-up of 22 months from the beginning of PARPi therapy, 57 patients relapsed (median PFS: 12 months) and 64 patients died (median OS: 23 months). During multivariable analysis, receiving PLD-Ox before PARPi was associated with improved PFS [hazard ratio (HR): 0.46, 95% CI: 0.26-0.82] and OS (HR: 0.48, 95% CI: 0.27-0.83). In 36 BRCA-mutated patients, PLD-Ox was associated with improved PFS (2-year PFS: 70.0% versus 25.0%, p = 0.02) | ||
| 520 | |a Conclusion: Receiving PLD-Ox before PARPi may improve prognosis in platinum-sensitive advanced OC patients and may provide advantages in the BRCA-mutated subgroup | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BRCA mutated | |
| 650 | 4 | |a PARP inhibitors | |
| 650 | 4 | |a oxaliplatin | |
| 650 | 4 | |a pegylated liposomal doxorubicin | |
| 650 | 4 | |a platinum-sensitive epithelial ovarian cancer | |
| 700 | 1 | |a Baldoni, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Cavallin, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Grego, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Falci, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Nardin, Margherita |e verfasserin |4 aut | |
| 700 | 1 | |a Mammano, Enzo |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Torri, Valter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic advances in medical oncology |d 2009 |g 15(2023) vom: 31., Seite 17588359231173181 |w (DE-627)NLM19877978X |x 1758-8340 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g day:31 |g pages:17588359231173181 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/17588359231173181 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |b 31 |h 17588359231173181 | ||